연구동향 분석

기분장애 환자의 비만에 대한 약물치료

손인기 이규항 Sohn, Inki Lee, Kyu-Hang 2014년

논문상세정보
인용/피인용
' 기분장애 환자의 비만에 대한 약물치료' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • mood disorder
  • obesity
  • pharmacotherapy
  • 기분장애
  • 비만
  • 약물치료
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,033 0

0.0%

' 기분장애 환자의 비만에 대한 약물치료' 의 참고문헌

  • 한국형 양극성 장애 약물치료 알고리듬 2014: 안정성과 내약성
    손인기 대한정신약물학회지 25 (4) : 161 ~ 167 [2014]
  • 비만의 행동중재와 약물치료
    김미경 대한내과학회지 84 (5) : 624 ~ 628 [2013]
  • 비만의 약물치료: 허가된 약물을 중심으로
    김경수 대한비만학회지 21 (4) : 197 ~ 202 [2012]
  • 비만의 약물 요법
    김경곤 대한의사협회지 54 (4) : 409 ~ 418 [2011]
  • Zonisamide for weight loss in obese adults: a randomized controlled trial
    Gadde KM JAMA 289 : 1820 ~ 1825 [2003]
  • Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults
    Berrington de Gonzalez A N Engl J Med 363 : 2211 ~ 2219 [2010]
  • Weight loss and quality of life in chronic heart failure patients
    Mariotti R J Cardiovasc Med(Hagerstown) 9 : 576 ~ 580 [2008]
  • Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine
    Assuncao SS Rev Bras Psiquiatr 28 : 270 ~ 276 [2006]
  • Weight change with long-term duloxetine use in chronic painful conditions: an analysis of 16 clinical studies
    Gaynor P Int J Clin Pract 65 : 341 ~ 349 [2011]
  • Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity
    Makris AP Appetite 42 : 185 ~ 195 [2004]
  • Valvular heart disease associated with fenfluramine-phentermine
    Connolly HM N Engl J Med 337 : 581 ~ 588 [1997]
  • Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse
    Maina G J Affect Disord 99 : 247 ~ 251 [2007]
  • Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients
    Bustillo JR Neuropsychopharmacol 28 : 527 ~ 529 [2003]
  • Topiramate as an adjunctive treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain
    Ko YH Clin Neuropharmacol 28 : 169 ~ 175 [2005]
  • The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review
    Wulffele MG J Intern Med 256 : 1 ~ 14 [2004]
  • Sibutramine. A review of its contribution to the management of obesity
    McNeely W Drugs 56 : 1093 ~ 1124 [1998]
  • Rosiglitazone in the treatment of weight gain and metabolic dysfunction during olanzapine administration: a double-blind, placebo controlled pilot study
    Baptista T Society of Neuroscience Annual Meeting [2007]
  • Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers
    Zhi J J Clin Pharmacol 35 : 1103 ~ 1108 [1995]
  • Psychotic mania associated with fenfluramine and phentermine use
    Raison CL Am J Psychiatry 154 : 711 ~ [1997]
  • Product Information: TOPAMAX(R) oral tablets, oral sprinkle capsules, topiramate oral tablets, oral sprinkle capsules
    Ortho-McNeil Neurologics,Inc [2008]
  • Product Information: GLUCOPHAGE(R), GLUCOPHAGE (R) XR extended-release oral tablets, oral tablets, metformin hydrochloride extended-release oral tablets, oral tablets
    Bristol-Myers Squibb Company [2009]
  • Placebo-controlled t rial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine
    Ball MP Clin Schizophr Relat Psychoses 5 : 17 ~ 25 [2011]
  • Phentermine cardiovascular safety
    Rothman RB Am J Emerg Med 27 : 1010 ~ 1013 [2009]
  • Pharmacological management of atypical antipsychotic-induced weight gain
    Baptista T CNS Drugs 22 : 477 ~ 495 [2008]
  • Orlistat in the treatment of psychopharmacologically induced weight gain
    Anghelescu I J Clin Psycho Pharmacol 20 : 716 ~ 717 [2000]
  • Orlistat in the treatment of clozapine-induced hyperglycemia and weight[letter]
    Pavlovic ZM Eur Psychiatry 20 : 520 ~ [2005]
  • Orlistat in clozapine-or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial
    Joffe G J Clin Psychiatry 69 : 706 ~ 711 [2008]
  • Olanzapine-induced weight gain in patients with first-episode schizophrenia: a doubleblind, placebo-controlled study of fluoxetine addition
    Poyurovsky M Am J Psychiatry 159 : 1058 ~ 1060 [2002]
  • Obesity and related metabolic abnormalities during antipsychotic drug administration:mechanisms, management and research perspectives
    Baptista T Pharmacopsychiatry 35 : 205 ~ 219 [2002]
  • Obesity and cardiovascular disease:pathogenic mechanisms and potential benefits of weight reduction
    Douketis JD Semin Vasc Med 5 : 25 ~ 33 [2005]
  • Nizatidine treatment and its relationship with leptin levels in patients with olanzapine induced weight gain
    Atmaca M Human Psychopharmacol 18 : 457 ~ 461 [2003]
  • Nizatidine for the treatment of patients with quetiapine-induced weight gain
    Atmaca M Human Psychopharmacol 19 : 37 ~ 40 [2004]
  • Nizatidine for prevention of weight gain with olanzapine:a double-blind placebo-controlled trial
    Cavazzoni P Eur Neuropsychopharmacol 13 : 81 ~ 85 [2003]
  • Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial
    Baptista T Schizophr Res 93 : 99 ~ 108 [2007]
  • Metformin addition attenuates olanzapine-induced weight gain in drug-naive first episode schizophrenia patients: a double blind placebo-controlled study
    Wu RR Am J Psychiatry 165 : 352 ~ 358 [2008]
  • Meta-analysis: pharmacologic treatment of obesity
    Li Z Ann Intern Med 142 : 532 ~ 546 [2005]
  • Mania and mortality: why the excess cardiovascular risk in bipolar disorder?
    Murray DP Curr Psychiatry Rep 11 : 475 ~ 480 [2009]
  • Managing weight gain as a side effect of antidepressant therapy
    Deshmukh R1 Cleve Clin J Med 70 : 614 ~ 618 [2003]
  • Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo
    Weintraub M Clin Pharmacol Ther 51 : 586 ~ 594 [1992]
  • Life style intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial
    Wu RR JAMA 299 : 185 ~ 193 [2008]
  • Interventions to reduce weight gain in schizophrenia
    Faulkner G Cochrane Database Syst Rev : CD005148 ~ [2007]
  • Interactions of lipoprotein lipase with the active-site inhibitor tetrahydroli-pstatin (Orlistat)
    Lookene A Eur J Biochem 222 : 395 ~ 403 [1994]
  • Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study
    Nickel MK J Clin Psychopharmacol 25 : 211 ~ 217 [2005]
  • Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder
    Bowden CL Am J Psychiatry 163 : 1199 ~ 1201 [2006]
  • Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
    Flint A J Clin Invest 101 : 515 ~ 520 [1998]
  • Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial
    Bowden CL Int Clin Psychopharmacol 25 : 60 ~ 67 [2010]
  • Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
    Christensen R Lancet 370 : 1706 ~ 1713 [2007]
  • Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People
    김경곤 Yonsei Medical Journal 47 (5) : 614 ~ 625 [2006]
  • Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
    Després JP N Engl J Med 353 : 2121 ~ 2134 [2005]
  • Effects of liraglutide in the treatment of obesity:a randomised, double-blind, placebo-controlled study
    Astrup A Lancet 374 : 1606 ~ 1616 [2009]
  • Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder
    Sachs G Bipolar Disord 8 : 175 ~ 181 [2006]
  • Effectiveness of phenylpropanolamine in the management of moderate obesity
    Schteingart DE Int J Obes Relat Metab Disord 16 : 487 ~ 493 [1992]
  • Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers
    Weber C Eur J Clin Pharmacol 51 : 87 ~ 90 [1996]
  • Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects
    James WP N Engl J Med 363 : 905 ~ 917 [2010]
  • Effect of naltrexone plus bupropion on weight loss in overweight and obese adults(COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Greenway FL Lancet 376 : 595 ~ 605 [2010]
  • Double-blind, placebocontrolled investigation of amantadine for weight loss in subjects who gained weight with olanzapine
    Graham KA Am J Psychiatry 162 : 1744 ~ 1746 [2005]
  • Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder
    Pavuluri MN Bipolar Disord 12 : 593 ~ 605 [2010]
  • Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis
    Johansson K Obes Rev 10 : 564 ~ 575 [2009]
  • Current and potential drugs for treatment of drugs for treatment of obesity
    Bray GA Endocr Rev 20 : 805 ~ 875 [1999]
  • Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
    Henderson DC Am J Psychiatry 157 : 975 ~ 981 [2000]
  • Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013
    Yatham LN Bipolar Disord 15 : 1 ~ 44 [2013]
  • Bupropion for weight reduction
    Gadde KM Expert Rev Neurother 7 : 17 ~ 24 [2007]
  • Atypical antipsychotics and the burden of disease
    Simpson GM Am J Manag Care 11 : S235 ~ S241 [2005]
  • Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial
    Alvarez-Jimenez M J Clin Psychiatry 67 : 1253 ~ 1260 [2006]
  • Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients:a doubleblind placebo-controlled study
    Poyurovsky M Psychopharmacology 192 : 441 ~ 448 [2007]
  • Amantadine for weight gain associated with olanzapine treatment
    Deberdt W Eur Neuropsychopharmacol 15 : 13 ~ 21 [2005]
  • A randomized, double-blind, placebo-controlled trial of metformin in treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents
    Klein DJ Am J Psychiatry 163 : 2072 ~ 2079 [2006]
  • A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects
    Cercato C Int J Obes (Lond) 33 : 857 ~ 865 [2009]
  • A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression
    Frye MA Am J Psychiatry 164 : 1242 ~ 1249 [2007]
  • A controlled trial using ephedrine in the treatment of obesity
    Miller DS Int J Obes 10 : 159 ~ 160 [1986]
  • A case series describing orlistat use in patients on psychotropic medications
    Carpenter LL Med Health R I 87 : 375 ~ 377 [2004]